Literature DB >> 1691217

Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis.

L T Davis1, D M Duffy.   

Abstract

Telangiectatic matting are vessels less than 0.2 mm in diameter that may appear after sclerotherapy treatment of varicose or telangiectatic leg veins. It is a complication about which very little epidemiologic data have been formally accrued. Therefore, a retrospective analysis was conducted by reviewing the records of 2120 patients in a private practice setting. The overall incidence of telangiectatic matting in our patient population was 16%. To identify risk factors, in-depth comparative analysis of the databases of 160 of the patients who developed telangiectatic matting and a control group of 160 nonmatting patients was performed. Significantly more patients in the matting group were overweight, on hormones during treatment, and had both a family history and a longer duration of spider veins (p less than 0.05). Additionally, the matting group had a significantly higher proportion of people noting onset of their veins after excess hormonal states, relative to before excess hormonal states, than the nonmatting group. Age and excessive standing did not differ significantly between the two groups. The results of this study provide objective, predictive risk factors for the development of telangiectatic matting.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691217     DOI: 10.1111/j.1524-4725.1990.tb00043.x

Source DB:  PubMed          Journal:  J Dermatol Surg Oncol        ISSN: 0148-0812


  6 in total

1.  Injection sclerotherapy.

Authors:  Robert L Worthington-Kirsch
Journal:  Semin Intervent Radiol       Date:  2005-09       Impact factor: 1.513

Review 2.  [Guidelines for sclerotherapy of varicose veins : S2k guideline of the German Society of Phlebology (DGP) in cooperation with the following professional associations: DDG, DGA, DDG, BVP. German Version].

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-01       Impact factor: 0.751

Review 3.  Polidocanol for endovenous microfoam sclerosant therapy.

Authors:  David M Eckmann
Journal:  Expert Opin Investig Drugs       Date:  2009-12       Impact factor: 6.206

Review 4.  Sclerotherapy in the treatment of varicose veins : S2k guideline of the Deutsche Gesellschaft für Phlebologie (DGP) in cooperation with the following societies: DDG, DGA, DGG, BVP.

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-12       Impact factor: 0.751

5.  Use of brimonidine tartrate to resolve telangiectatic matting: case report.

Authors:  Brenno Augusto Seabra de Mello; Yasmin de Rezende Beiriz; Américo Carnelli Bonatto; Gustavo Sasso Benso Maciel; Laila Reggiani de Almeida; José Marcelo Corassa
Journal:  J Vasc Bras       Date:  2020-09-14

6.  A Novel Approach for the Treatment of Spider Veins.

Authors:  Mirsad Mujadzic; Edmond F Ritter; Kenna S Given
Journal:  Aesthet Surg J       Date:  2015-08-04       Impact factor: 4.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.